Articles dans des revues avec comité de lecture (396)
  1. 253. Awada, A., & Piccart-Gebhart, M. (2008). Une révolution dans l’approche du cancer du sein basée sur les progrès de la biologie moléculaire. Pan Arab Journal of Oncology, 1(2), 20-21.
  2. 254. Widakowich, C., Dinh, P., de Azambuja, E., Awada, A., & Piccart-Gebhart, M. (2008). HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? Anti-Cancer Agents in Medicinal Chemistry, 8(5), 488-496.
  3. 255. Neven, P., Paridaens, R., Pelgrims, G., Martens, M., Bols, A., Goeminne, J. C., Vindevoghel, A., Demol, J., Stragier, B., De Greve, J., Fontaine, C., Van Den Weyngaert, D., Becquart, D., Borms, M., Cocquyt, V., Van Den Broecke, R., Selleslags, J., Awada, A., Dirix, L. Y., Van Dam, P., Azerad, M. A., Vandenhoven, G., Christiaens, M. R., & Vergote, I. (2008). Fulvestrant (Faslodex) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast cancer research and treatment, 109(1), 59-65. doi:10.1007/s10549-007-9628-2
  4. 256. Awada, A., Albanell, J., Canney, P. A., Dirix, L. Y., Gil, T., Cardoso, F., Gascon, P., Piccart-Gebhart, M., & Baselga, J. (2008). Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. British Journal of Cancer, 98(9), 1500-1507. doi:10.1038/sj.bjc.6604347
  5. 257. Kraft Rovere, R., & Awada, A. (2008). Treatment of recurrent thyroid cancers--is there a light in the horizon? Current opinion in oncology, 20(3), 245-248. doi:10.1097/CCO.0b013e3282fb289a
  6. 258. Awada, A., & Torti, F. F. (2008). Editorial Introductions. Current opinion in oncology, 20(3), 7-8. doi:10.1097/CCO.0b013e328300090f
  7. 259. Takimoto, C. H., & Awada, A. (2008). Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer chemotherapy and pharmacology, 61(4), 535-548. doi:10.1007/s00280-007-0639-9
  8. 260. Larsimont, D., Durbecq, V., Awada, A., & Di Leo, A. (2008). HER2 et topo-isomérase II alpha: deux marqueurs d'intérêt clinique dans le cancer du sein. Bulletin du cancer, 95(3), 344-351. doi:10.1684/bdc.2008.0596
  9. 261. Bauvet, F., Klastersky, J., & Awada, A. (2008). Soins de support en oncologie: concepts, accomplissements et nouveaux défis. Bulletin du cancer, 95(3), 381-388. doi:10.1684/bdc.2008.0586
  10. 262. Awada, A., & Storme, G. A. (2008). Oncology in Belgium: a global approach where research and clinic are joining. Bulletin du cancer, 95(3), 265. doi:10.1684/bdc.2008.0614
  11. 263. Awada, A., & Piccart-Gebhart, M. (2008). Management of HER-2/neu-positive metastatic breast cancer. European journal of cancer, 6(4), 2-9. doi:10.1016/j.ejcsup.2007.12.001
  12. 264. Ismael, G., Rosa, D. D., Mano, M. S., & Awada, A. (2008). Novel cytotoxic drugs: old challenges, new solutions. Cancer treatment reviews, 34(1), 81-91. doi:10.1016/j.ctrv.2007.08.001
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>